LFM
REGN icon

LGT Fund Management’s Regeneron Pharmaceuticals REGN Stock Holding History

LGT Fund Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-314
Closed -$243K – 263
2026
Q1 		$243K Sell
314
-167
-35% -$128K 0.01% 237
2025
Q4 		$372K Hold
481
– – 0.03% 192
2025
Q3 		$289K Sell
481
-94
-16% -$53.1K 0.02% 214
2025
Q2 		$302K Sell
575
-83
-13% -$46.3K 0.03% 207
2025
Q1 		$417K Buy
658
+98
+18% +$67.4K 0.04% 193
2024
Q4 		$399K Buy
560
+108
+24% +$90.6K 0.03% 204
2024
Q3 		$470K Sell
452
-44
-9% -$49K 0.05% 161
2024
Q2 		$521K Buy
+496
New +$481K 0.07% 146

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

LGT Fund Management's REGN Position: Q2 2026 in Review

LGT Fund Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 314 shares — an estimated $243K sold.

LGT Fund Management first reported a position in REGN in Q2 2024 and held it in 8 quarters. The position peaked at $521K in Q2 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • LGT Fund Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • LGT Fund Management sold 314 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $243K.
  • LGT Fund Management first reported a position in Regeneron Pharmaceuticals in Q2 2024 and held it in 8 quarters.
  • LGT Fund Management's Regeneron Pharmaceuticals position peaked at $521K in Q2 2024.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on LGT Fund Management's 13F filing for Q2 2026, filed 10 Aug 2026.